Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis

BACKGROUND: A pre-specified meta-analysis of cardiovascular (CV) events from 21 phase 2b/3 dapagliflozin clinical trials was undertaken to characterise the CV profile of dapagliflozin. This showed no increase in CV risk with dapagliflozin compared with control (placebo or comparator treatment) with...

Descripción completa

Detalles Bibliográficos
Autores principales: Sonesson, Christian, Johansson, Peter A., Johnsson, Eva, Gause-Nilsson, Ingrid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4761166/
https://www.ncbi.nlm.nih.gov/pubmed/26895767
http://dx.doi.org/10.1186/s12933-016-0356-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4761166/
https://www.ncbi.nlm.nih.gov/pubmed/26895767
http://dx.doi.org/10.1186/s12933-016-0356-y

Ejemplares similares